Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceutical company PharmaMar, has secured MHRA approval for Zepzelca (lurbinectedin) combined with atezolizumab as first-line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy.
Lurbinectedin is a selective inhibitor of oncogenic transcription derived from a marine compound and targets transcriptional addiction in tumour cells and tumour-associated macrophages.
The decision is supported by Phase 3 IMforte trial data which found that the combination reduced the risk of disease progression or death by 46% and the risk of death by 27% versus atezolizumab alone. Median overall survival was 13.2 months compared with 10.6 months (HR=0.73; 95% CI: 0.57–0.95; p=0.0174). Median progression-free survival was 5.4 months versus 2.1 months (HR=0.54; 95% CI: 0.43–0.67; p
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research